{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:28:40Z","timestamp":1786649320705,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of brachytherapy in patients with uveal melanoma and retinal vascular tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Patients who received Ruthenium-106 (Ru-106) plaque brachytherapy at the Torfeh Medical Center between March 2016 and March 2022 were examined in this retrospective case-series. We collected clinical data on tumor features, treatment details, and patient outcomes. These data were analyzed using SPSS software. Tumor regression was the primary outcome that was monitored, with complications being evaluated as secondary outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of the 80 patients, 55 had melanoma, 21 had vasoproliferative tumor (VPT), and 4 had retinal capillary hemangioma (RCH). Tumor regression was observed in 74.5% of melanoma cases and 100% of VPT\/RCH cases. Significant relationships were found between tumor characteristics, such as thickness and dose rate at the apex, and treatment outcomes. Complications included radiation retinopathy and cataract formation, with recurrence rates of 16.4% in melanoma and 7.7% in VPT\/RCH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Ru-106 plaque brachytherapy is effective in treating various intraocular tumors, particularly VPT\/RCH. Tumor thickness significantly influences treatment outcomes, emphasizing the need for tailored approaches in brachytherapy planning. However, small sample sizes for specific tumor types limited the generalization of the outcomes. Future research should focus on refining techniques and mitigating complications to improve patient outcomes in ocular oncology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/joco.joco_248_24","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T14:00:54Z","timestamp":1766152854000},"page":"247-255","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Outcome of Ruthenium-106 Brachytherapy for Uveal Melanoma and Retinal Vascular Tumors: A Retrospective Study"],"prefix":"10.4103","volume":"37","author":[{"given":"Saeed","family":"Karimi","sequence":"first","affiliation":[{"name":"Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran"},{"name":"Department of Ophthalmology, Torfeh Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadra","family":"Ashrafi","sequence":"additional","affiliation":[{"name":"Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyyed Morteza","family":"Hosseini Imeni","sequence":"additional","affiliation":[{"name":"Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Siavashpour","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shohada-e Tajrish Educational Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"R1-20251222","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/ceo.14353","article-title":"Disease burden, risk factors, and temporal trends of eye cancer: A global analysis of cancer registries","volume":"52","author":"Huang","year":"2024","journal-title":"Clin Exp Ophthalmol"},{"key":"R2-20251222","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2214-109X(20)30488-5","article-title":"The lancet global health commission on global eye health: Vision beyond 2020","volume":"9","author":"Burton","year":"2021","journal-title":"Lancet Glob Health"},{"key":"R3-20251222","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/s41598-022-26349-x","article-title":"A joinpoint and age-period-cohort analysis of ocular cancer secular trends in Iran from 2004 to 2016","volume":"13","author":"Abolhosseini","year":"2023","journal-title":"Sci Rep"},{"key":"R4-20251222","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2147\/OPTH.S129645","article-title":"Brachytherapy for patients with uveal melanoma: Historical perspectives and future treatment directions","volume":"12","author":"Brewington","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"R5-20251222","first-page":"5281","article-title":"Brachytherapy of uveal melanomas with ruthenium-106 plaques","volume":"17","author":"Bela\u00efd","year":"2016","journal-title":"Asian Pac J Cancer Prev"},{"key":"R6-20251222","doi-asserted-by":"crossref","first-page":"392","DOI":"10.5114\/jcb.2019.87407","article-title":"Complications and adverse events of plaque brachytherapy for ocular melanoma","volume":"11","author":"Peddada","year":"2019","journal-title":"J Contemp Brachytherapy"},{"key":"R7-20251222","doi-asserted-by":"crossref","first-page":"11297","DOI":"10.1038\/s41598-020-68232-7","article-title":"Forty-year prognosis after plaque brachytherapy of uveal melanoma","volume":"10","author":"St\u00e5lhammar","year":"2020","journal-title":"Sci Rep"},{"key":"R8-20251222","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/bjo.14.4.145","article-title":"Choroidal sarcoma treated by the intraocular insertion of radon seeds","volume":"14","author":"Moore","year":"1930","journal-title":"Br J Ophthalmol"},{"key":"R9-20251222","doi-asserted-by":"crossref","first-page":"S912","DOI":"10.4103\/jcrt.jcrt_1004_22","article-title":"Safety and efficacy of indigenously developed ruthenium-106 eye plaque for brachytherapy of a spectrum of ocular tumors: A case series","volume":"19","author":"Kumar","year":"2023","journal-title":"J Cancer Res Ther"},{"key":"R10-20251222","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13014-020-01621-4","article-title":"(106) ruthenium eye plaque brachytherapy in the management of medium sized uveal melanoma","volume":"15","author":"Jiang","year":"2020","journal-title":"Radiat Oncol"},{"key":"R11-20251222","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1177\/112067210901900420","article-title":"Long-term choroidal vascular changes after iodine brachytherapy versus transpupillary thermotherapy for choroidal melanoma","volume":"19","author":"Pilotto","year":"2009","journal-title":"Eur J Ophthalmol"},{"key":"R12-20251222","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.ophtha.2006.10.039","article-title":"Incidence of cataract and outcomes after cataract surgery in the first 5 years after iodine 125 brachytherapy in the collaborative ocular melanoma study: COMS report no.27","volume":"114","year":"2007","journal-title":"Ophthalmology"},{"key":"R13-20251222","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s00417-016-3356-4","article-title":"Cataract development in patients treated with proton beam therapy for uveal melanoma","volume":"254","author":"Seibel","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R14-20251222","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/eye.2016.275","article-title":"Uveal melanoma: Relatively rare but deadly cancer","volume":"31","author":"Kaliki","year":"2017","journal-title":"Eye (Lond)"},{"key":"R15-20251222","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.survophthal.2025.01.001","article-title":"Clinical features, diagnosis, management, and prognosis of circumscribed choroidal hemangioma","volume":"70","author":"Yang","year":"2025","journal-title":"Surv Ophthalmol"},{"key":"R16-20251222","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1001\/archopht.120.7.933","article-title":"Combined plaque radiotherapy and transpupillary thermotherapy for choroidal melanoma: Tumor control and treatment complications in 270 consecutive patients","volume":"120","author":"Shields","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"R17-20251222","doi-asserted-by":"crossref","first-page":"754108","DOI":"10.3389\/fonc.2021.754108","article-title":"Long-term outcomes in uveal melanoma after ruthenium-106 brachytherapy","volume":"11","author":"Cennamo","year":"2022","journal-title":"Front Oncol"},{"key":"R18-20251222","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1016\/j.prro.2013.08.004","article-title":"Disease control and toxicity outcomes using ruthenium eye plaque brachytherapy in the treatment of uveal melanoma","volume":"4","author":"Takiar","year":"2014","journal-title":"Pract Radiat Oncol"},{"key":"R19-20251222","first-page":"31","article-title":"Ruthenium-106 plaque radiotherapy for retinal vasoproliferative tumors","volume":"21","author":"Naseripour","year":"2009","journal-title":"J Curr Ophthalmol"},{"key":"R20-20251222","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1007\/s10792-020-01386-5","article-title":"Ru-106 plaque radiotherapy for vasoproliferative tumors of retina: A 15-year single-center experience","volume":"40","author":"Abolfathzadeh","year":"2020","journal-title":"Int Ophthalmol"},{"key":"R21-20251222","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.brachy.2021.05.162","article-title":"Long-term outcomes after enucleation or plaque brachytherapy of choroidal melanomas touching the optic disc","volume":"20","author":"Fili","year":"2021","journal-title":"Brachytherapy"},{"key":"R22-20251222","doi-asserted-by":"crossref","first-page":"303","DOI":"10.5114\/jcb.2020.98108","article-title":"Eye plaque brachytherapy versus enucleation for ocular melanoma: An analysis from the National Cancer Database","volume":"12","author":"Messer","year":"2020","journal-title":"J Contemp Brachytherapy"},{"key":"R23-20251222","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/archopht.117.5.609","article-title":"Radiation retinopathy following plaque radiotherapy for posterior uveal melanoma","volume":"117","author":"G\u00fcnd\u00fcz","year":"1999","journal-title":"Arch Ophthalmol"},{"key":"R24-20251222","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.ajo.2009.11.006","article-title":"Risk factors for radiation maculopathy after ophthalmic plaque radiation for choroidal melanoma","volume":"149","author":"Finger","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"R25-20251222","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.ophtha.2009.10.015","article-title":"Proliferative radiation retinopathy after plaque radiotherapy for uveal melanoma","volume":"117","author":"Bianciotto","year":"2010","journal-title":"Ophthalmology"},{"key":"R26-20251222","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1177\/11206721231215105","article-title":"Post-operative interventional radiotherapy (brachytherapy) in advanced ocular surface and eyelid tumors as an alternative to surgical retreatment","volume":"34","author":"Cuffaro","year":"2024","journal-title":"Eur J Ophthalmol"},{"key":"R27-20251222","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ajo.2023.12.005","article-title":"Retrospective analysis of radiation-induced complications of uveal melanoma patients treated with brachytherapy in the era of anti-VEGF","volume":"260","author":"Hasegawa","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"R28-20251222","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.2147\/OPTH.S433531","article-title":"Efficacy of prophylactic anti-VEGF in preventing radiation retinopathy: A systematic review and meta-analysis","volume":"17","author":"Victor","year":"2023","journal-title":"Clin Ophthalmol"},{"key":"R29-20251222","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/s41433-022-01944-4","article-title":"Long-term visual outcomes after ruthenium plaque brachytherapy for posterior choroidal melanoma","volume":"37","author":"O'Day","year":"2023","journal-title":"Eye (Lond)"},{"key":"R30-20251222","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0360-3016(93)90277-3","article-title":"High intensity 125-iodine (125I) plaque treatment of uveal melanoma","volume":"26","author":"Quivey","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R31-20251222","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.124.12.1684","article-title":"The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V.Twelve-year mortality rates and prognostic factors: COMS report. no. 28","volume":"124","year":"2006","journal-title":"Arch Ophthalmol"}],"container-title":["Journal of Current Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/joco.joco_248_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:52:26Z","timestamp":1786647146000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/joco.joco_248_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/joco.joco_248_24","relation":{},"ISSN":["2452-2325"],"issn-type":[{"value":"2452-2325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"2024-11-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}